Interferons and Interferon (IFN)-inducible Protein 10 During Highly Active Anti-retroviral Therapy (HAART)-possible Immunosuppressive Role of IFN-alpha in HIV Infection
Overview
Affiliations
Interferons play an important, but incompletely understood role in HIV-related disease. We investigated the effect of HAART on plasma levels of IFN-alpha, IFN-gamma, neopterin and interferon-inducible protein 10 (IP-10) in 41 HIV-infected patients during 78 weeks of therapy. At baseline HIV-infected patients had raised levels of both IP-10 and IFN-alpha compared with healthy controls (n = 19), with particularly high levels in advanced disease. HAART induced a marked decrease in levels of both IFN-alpha, neopterin and IP-10, though not to normal concentrations. In contrast, IFN-gamma levels were low throughout the study, and not different from controls. While neopterin and IP-10 remained significantly decreased compared with baseline levels throughout the study, IFN-alpha levels returned to baseline at the end of the study. Persistently high IP-10 and IFN-alpha levels were associated with immunological treatment failure and even high baseline levels of IFN-alpha appeared to predict immunological relapse. Furthermore, we found a markedly suppressive effect of exogenously added IFN-alpha on phytohaemagglutinin-stimulated lymphocyte proliferation in both patients and controls, and this suppressive effect seemed not to involve enhanced lymphocyte apoptosis. Our findings suggest a pathogenic role of IFN-alpha in HIV infection, which may be a potential target for immunomodulating therapy in combination with HAART.
Poveda E, Fitzgerald W, Alonso-Dominguez J, Aguayo-Arjona J, Marino A, Alvarez H Front Immunol. 2024; 15:1446730.
PMID: 39267749 PMC: 11390527. DOI: 10.3389/fimmu.2024.1446730.
CXCL10 Chemokine: A Critical Player in RNA and DNA Viral Infections.
Elemam N, Talaat I, Maghazachi A Viruses. 2022; 14(11).
PMID: 36366543 PMC: 9696077. DOI: 10.3390/v14112445.
Russo E, Nannini G, Sterrantino G, Kiros S, Di Pilato V, Coppi M World J Gastroenterol. 2022; 28(6):635-652.
PMID: 35317423 PMC: 8900548. DOI: 10.3748/wjg.v28.i6.635.
Fueyo-Gonzalez F, McGinty M, Ningoo M, Anderson L, Cantarelli C, Angeletti A Immunity. 2022; 55(3):459-474.e7.
PMID: 35148827 PMC: 8917088. DOI: 10.1016/j.immuni.2022.01.011.
Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features.
Bartsch Y, Loos C, Rossignol E, Fajnzylber J, Yuan D, Avihingsanon A mBio. 2021; 12(2).
PMID: 33688003 PMC: 8092214. DOI: 10.1128/mBio.00170-21.